Local Coverage DeterminationClinical Laboratory

LCD L36692: Vitamin D Assay Testing — Noridian

LCD-L36692

Document details

Document type
Local Coverage Determination
Issuing body
MAC Contractor
Document ID
LCD-L36692
Published
June 5, 2026
Effective date
August 14, 2025
MAC region
Noridian

Summary

The introduction of the new LCD for Vitamin D Assay Testing by Noridian may affect billing practices, ensuring that healthcare providers follow updated guidelines for testing reimbursement. As a resul

New LCD for Vitamin D testing impacts billing procedures.

Affected codes

ICD-10-CM

Affected specialty

Clinical Laboratory alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36692&ver=27

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

4

CMS Transmittal R13849CP: Changes to the Laboratory National Coverage Determination (NCD) Edit Software for October 2026…

Policy CMS-T-R13849CP · Clinical Laboratory

Critical

CMS is updating the Laboratory NCD Edit Software effective October 5, 2026, to reflect changes in National Coverage Determinations for lab services. Billing teams must review updated NCD edits in thei

View alert

CMS Transmittal R13855CP: July 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…

Policy CMS-T-R13855CP · Clinical Laboratory

Critical

This transmittal implements the July 2026 quarterly update to the Clinical Laboratory Fee Schedule (CLFS), effective July 6, 2026. Billing teams must update their lab fee schedule tables to reflect th

View alert

LCD L39044: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — WPS

Policy LCD-L39044 · Clinical Laboratory

High

The LCD L39044 focuses on coverage for molecular syndromic panels for infectious disease pathogen identification. As a final LCD, it is currently active and will be effective starting June 25, 2026, i

View alert

LCD L40272 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS

Policy LCD-L40272 · Clinical Laboratory

Critical

LCD L40272 establishes coverage criteria for MolDX biomarker testing in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), ef

View alert